Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features

Haematologica

Volumn 96, Issue 11, 2011, Pages 1720-1722

  Ross, David M ^a,b   Bartley, Paul A ^b   Goyne, Jarrad ^a   Morley, Alexander A ^b   Seymour, John F ^c   Grigg, Andrew P ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

Cml; Complete molecular response; Dasatinib; Imatinib

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DASATINIB; DNA; IMATINIB; MESSENGER RNA; NILOTINIB; PREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE CLONE; LYMPHOCYTOSIS; MALE; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ADULT; FEMALE; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; RNA, NEOPLASM; THIAZOLES;

EID: 80355125811     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.048165     Document Type: Article

References (8)

1. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 2010;116 (8):1329-35.
2. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719-24.
3. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-35.
4. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic- phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.
5. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362 (24):2251-9.
6. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol. 2010;32(6 Pt 1):e222-8.
7. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-5.
8. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398-405